{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:12:50Z","timestamp":1780495970496,"version":"3.54.1"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The relative efficacy and safety of tofacitinib and upadacitinib were assessed in patients with rheumatoid arthritis (RA) with an inadequate response to conventional synthetic (cs) or biologic (b) disease\u2010modifying anti\u2010rheumatic drugs (DMARDs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We performed a Bayesian network meta\u2010analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tofacitinib and upadacitinib in combination with methotrexate (MTX) in RA patients with an inadequate cs\u2010 or b\u2010DMARD response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine RCTs including 5794 patients met the inclusion criteria. There were 15 pairwise comparisons including 10 direct comparisons of 6 interventions. Upadacitinib 15\u00a0mg\u00a0+\u00a0MTX and upadacitinib 30\u00a0mg\u00a0+\u00a0MTX were among the most effective treatments for active RA with an inadequate cs\u2010 or b\u2010DMARD response, followed by tofacitinib 10\u00a0mg\u00a0+\u00a0MTX, tofacitinib 5\u00a0mg\u00a0+\u00a0MTX, and adalimumab\u00a0+\u00a0MTX. Ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that upadacitinib 15\u00a0mg\u00a0+\u00a0MTX and upadacitinib 30\u00a0mg\u00a0+\u00a0MTX had the highest probability of being the best treatment in terms of the American College of Rheumatology 20 response rate (SUCRA\u00a0=\u00a00.820, 0.762), followed by tofacitinib 10\u00a0mg\u00a0+\u00a0MTX (SUCRA\u00a0=\u00a00.623), tofacitinib 5\u00a0mg\u00a0+\u00a0MTX (SUCRA\u00a0=\u00a00.424), adalimumab\u00a0+\u00a0MTX (SUCRA\u00a0=\u00a00.371), and placebo\u00a0+\u00a0MTX (SUCRA\u00a0=\u00a00.001). No significant differences were observed in the incidence of serious adverse events after treatment with tofacitinib\u00a0+\u00a0MTX, upadacitinib\u00a0+\u00a0MTX, adalimumab\u00a0+\u00a0MTX, or placebo\u00a0+\u00a0MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In RA patients with an inadequate response to cs\u2010 or b\u2010DMARDs, upadacitinib 15\u00a0mg\u00a0+\u00a0MTX and upadacitinib 30\u00a0mg\u00a0+\u00a0MTX were the most efficacious interventions and were not associated with significant risks of serious adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13616","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T13:07:17Z","timestamp":1560863237000},"page":"1563-1571","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"22","author":[{"given":"Gwan Gyu","family":"Song","sequence":"first","affiliation":[{"name":"Department of Rheumatology Korea University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Korea University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Korea University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R700016200"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.07.038"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1087061"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.05.020"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199404000-00003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61115-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2000.tb00733.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780166"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200007000-00011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2994-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-0038-1642454","article-title":"Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome","volume":"71","author":"Yamazaki M","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1001895"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24123"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051263"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-110"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2012.01712.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12455847"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200010)43:10<2349::AID-ANR24>3.0.CO;2-J"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/107602960000600301"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2146\/news120088","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor K","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30151-1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/096120339400300312"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.354"},{"key":"e_1_2_7_38_1","first-page":"1","article-title":"Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta\u2010analysis of randomized controlled trials","author":"Bae S\u2010C","year":"2018","journal-title":"Zeitschrift f\u00fcr Rheumatologie"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2017.24.4.227"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T06:50:30Z","timestamp":1694328630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1756-185X.13616"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13616","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"2019-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}